Siemens Healthineers AG (WBO:SHL) ROCE % : 8.14% (As of Dec. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Siemens Healthineers AG ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Siemens Healthineers AG's annualized ROCE % for the quarter that ended in Dec. 2024 was 8.14%.

Siemens Healthineers AG ROCE % Historical Data

The historical data trend for Siemens Healthineers AG's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Siemens Healthineers AG ROCE % Chart

Siemens Healthineers AG Annual Data

Trend

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Sep24

ROCE %

Get a 7-Day Free Trial

12.07

9.97

8.44

6.33

8.86

Siemens Healthineers AG Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
ROCE %	Get a 7-Day Free Trial															7.83	7.60	8.02	11.28	8.14

Siemens Healthineers AG ROCE % Calculation

Siemens Healthineers AG's annualized ROCE % for the fiscal year that ended in Sep. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Sep. 2024 )		(A: Sep. 2023 )		(A: Sep. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Sep. 2024 )		(A: Sep. 2023 )		(A: Sep. 2024 )
	=	2999	/	( ( (46684 - 13440)	+	(46055 - 11573) )	/ 2 )
	=	2999	/	( (33244	+	34482)	/ 2 )
	=	2999	/	33863
	=	8.86 %

Siemens Healthineers AG's ROCE % of for the quarter that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	2900	/	( ( (46055 - 11573)	+	(48317 - 11547) )	/ 2 )
	=	2900	/	( ( 34482	+	36770 )	/ 2 )
	=	2900	/	35626
	=	8.14 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2024) EBIT data.

Siemens Healthineers AG (WBO:SHL) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Siemens Healthineers AG ROCE % Related Terms

Thank you for viewing the detailed overview of Siemens Healthineers AG's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Siemens Healthineers AG Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Siemens Healthineers AG (WBO:SHL) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

SEMHF:USA SMMNY:USA 1SHL:Italy SHLd:UK 0PMJ:UK SHL:Germany SHL:Bulgaria

Address

Siemensstrasse 3, Forchheim, BY, DEU, 91301

Website

https://www.siemens-healthineers.com

Siemens Healthineers is engaged in therapeutic imaging, radiotherapy, laboratory, and point-of-care diagnostics. The imaging segment (55% of sales in fiscal 2023) includes magnetic resonance imaging, computed tomography, X-ray systems, molecular imaging, and ultrasound. The Varian segment (16% of sales) offers radiotherapy and other oncology solutions. The portfolio of the diagnostics segment (21%) includes in vitro diagnostics products offered to providers and point-of-care diagnostics. The advanced therapies segment (9%) products are designed to support image-guided minimally invasive treatments in cardiology, interventional radiology, and surgery. North America represents 41% of total sales, Europe, Middle East, and Africa 32%, and Asia-Pacific including China the remainder.

Siemens Healthineers AG Headlines

No Headlines